期刊文献+

Hsp22对SCA3/MJD转基因果蝇的神经保护作用研究 被引量:5

Research on Neuroprotective Role of Hsp22 in SCA3/MJD Transgenic Drosophila Models
下载PDF
导出
摘要 为了探讨Hsp22在SCA3/MJD发病机制中的作用.选用GMR-GAL4和elav-GAL4驱动子,利用经典的GAL4-UAS系统,将含有78个CAG重复扩增的ataxin-3蛋白片段(MJDtr-Q78)分别在果蝇眼睛和神经系统选择性表达,构建GMR-GAL4/UAS和elav-GAL4/UAS系统SCA3/MJD转基因果蝇模型,然后利用遗传学方法和热休克反应使Hsp22在SCA3/MJD转基因果蝇眼睛和神经系统以不同水平过表达.结果表明,Hsp22过表达显著抑制了MJDtr-Q78蛋白的神经毒性,果蝇眼睛视网膜光感受神经元变性明显缓解,果蝇存活能力也显著提高.Hsp22对SCA3/MJD具有保护作用,增强Hsp22表达对SCA3/MJD可能是一种潜在的治疗方法. To confer the influence of Hsp22 on pathogenesis of SCA3/MJD. GMR-GAL4 and elav-GAL4 system SCA3/MJD transgenic Drosophila models were constructed by using the promoter GMR-GAL4 and elav-GAL4 which drive target selective gene expression in developing eyes and neurons, respectively. Then, Hsp22 protein was overexpressed in SCA3/MJD transgenic Drosophila models at different levels by genetic methods and heat shock reaction. Overexpression of endogen Drosophila Hsp22 can notably suppress the neurotoxicity of MJDtr-Q78 protein, and the level of lisp22 expression was in consistent with rehabilitation for neurodegeneration of Drosophila eyes, and extension of Drosophila lifespan. It is firstly confirmed that expression of Hsp22 protects the SCA3/MJD from neurodegeneration on Drosophila models, which might contribute to a potential therapeutic effect on SCA3/MJD.
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2008年第12期1430-1436,共7页 Progress In Biochemistry and Biophysics
基金 国家高技术研究发展计划项目(863)(2004AA227040) 国家"十一五"支撑计划项目(2006BA105A07) 国家"十五"攻关计划项目(2004BA720A03) 国家自然科学基金项目(30871354 30710303061 30400262) 湖南省自然科学基金重点项目(08JJ3048)~~
关键词 遗传性脊髓小脑性共济失调3型 ATAXIN-3 Hsp22 转基因果蝇模型 神经保护 SCA3, ataxin-3, Hsp22, transgenic Drosophila models, neuroprotection
  • 相关文献

参考文献21

  • 1Tang B, Liu C, Shen L, et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCAT, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neurol, 2000, 57(4): 540-544.
  • 2Jiang H, Tang B, Xia K, et al. Spinocerebellar ataxia type 6 in China's Mainland: Molecular and clinical features in four families. J Neurol Sci, 2005, 236(1 -2): 25-29.
  • 3Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet, 1994, 8(3): 221-228.
  • 4Durr A, Stevanin G, Cancel G. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular and neuropathologic features. Ann Neurol, 1996, 39(4): 490-499.
  • 5Tang B S, Zhao G H, Luo W, et al Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet, 2005, 116(3): 222-224.
  • 6Yu S, Thomas H M. The small heat shock proteins and their role in human disease. FEBS J, 2005, 272(11): 2613-2627.
  • 7Kurapati R, Passananti H B, Rose M R, et al Increased hsp22 RNA levels in Drosophila lines genetically selected increased longevity. J Gerontol A Biol Sci Med Sci, 2000, 55(11): B552-559.
  • 8Ross C A, Poirier M A. Protein aggregation and neurodegenerative disease. Nat Med, 2004, 10(Suppl): S 10 -17.
  • 9Kazemi-Esfarjani P, Benzer S. Genetic suppression ofpolyglutamine toxicity in Drosophila. Science, 2000, 287(5459): 1837-1840.
  • 10Warrick J M, Paulson H L, Gray-Board G L. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell, 1998, 93(6): 939-949.

同被引文献67

  • 1汤建光,沈璐,唐北沙,张玉虎,江泓,廖书胜,张海南,王春喻,夏昆,潘乾.SUMO-1共价修饰ataxin-3[J].生物化学与生物物理进展,2006,33(11):1037-1043. 被引量:8
  • 2Anne-Laurence B, Caroline R, Irina P, et al. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell Biochem, 2007, 41:263-293.
  • 3Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell, 2009, 101: 193-205.
  • 4Hahnen E, Hauke J, Trankle C, et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Inves Drugs, 2008, 17:169-184.
  • 5Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 2007, 26:5310- 5318.
  • 6Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neuroehem, 2008, 106:2119-2130.
  • 7Hisahara S, Chiba S, Matsumoto H, et al. Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRTI(Sir2α). J Pharmacol Sci, 2005, 98:200-204.
  • 8Liu H, Hu Q, Kaufman A, et al. Developmental expression of histone deaeetylase 11 in the murine brain. J Neurosci Res, 2008, 86:537-543.
  • 9Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci, 2005, 25:9544-9553.
  • 10Lawless MW, Norris S, O' Byrne K J, et al. Targeting histone deaeetylases for the treatment of immune, endocrine & metabolic disorders. Endocr Metab Immune Disord Drug Targets, 2009, 9: 84 -107.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部